1952 (1952) News
Follow 1952 (1952) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Everest Medicines wins China NMPA approval for CARDAMYST nasal spray
Everest Medicines says China’s NMPA approved CARDAMYST (etripamil) nasal spray to convert acute symptomatic PSVT to sinus rhythm in adults, providing an out-of-hospital, self-administered option.
REGULATION | Sep 21, 2026, 03:28 AM UTC
M
Everest Medicines gets NMPA approval for Cardamyst NDA in adult PSVT
Everest Medicines Limited says China’s NMPA approved its Cardamyst (etripamil) NDA for treating PSVT in adults.
GEOPOLITICS | Sep 03, 2026, 03:50 PM UTC
M
Everest Medicines gets NMPA approval for CARDAMYST in adult PSVT
Everest Medicines said China’s NMPA approved CARDAMYST (etripamil) to convert acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
GEOPOLITICS | Sep 03, 2026, 03:01 PM UTC